Anti-Mouse RANKL/CD254 Antibody (IK22/5) is an anti-mouse RANKL/CD254 IgG2a monoclonal antibody. Anti-Mouse RANKL/CD254 Antibody (IK22/5) inhibits osteoclast formation and activity by specifically blocking the binding of RANKL and RANK. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can inhibit the expression of MuRF1 /Trogin-1 and activation of NF-κB. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can be used for research on cancer such as melanoma or colon cancer and osteoporosis [1] [2] [3].
In Vivo, Anti-Mouse RANKL/CD254 Antibody (IK22/5) (300 μg/mouse, i.p., three times per week, for 14-21 days) significantly reduces bone erosion and osteoporosis in male DBA/1 mice with collagen induced arthritis (CIA)[1]. Anti-Mouse RANKL/CD254 Antibody (IK22/5) (200 μg, i.p., on day -1, 0, and 2) significantly reduces the number of lung metastatic nodules combined with anti-CTLA4 mAb in C57BL/6 wild-type (WT) mice bearing B16F10 or RM-1 lung metastasis[2]. Anti-Mouse RANKL/CD254 Antibody (IK22/5) (200 μg, i.p., once every 2-4 days, from day 3 to 12) significantly inhibits tumor growth combined with anti-CTLA4 mAb in C57BL/6 WT mice bearing B16F10 tumors or CT26 tumors[2]. Anti-Mouse RANKL/CD254 Antibody (IK22/5) (100 or 250 μg, i.p., twice weekly, for 24 weeks) significantly improves muscle atrophy and its function in female C57BL/6 mice with a cigarette smoke (CS) exposure induced chronic obstructive pulmonary disease (COPD) model[3].
In Vitro, Anti-Mouse RANKL/CD254 Antibody (IK22/5) (3-5 days) dose dependently inhibits osteoclast differentiation by blocking the RANKL/RANK interaction in mouse RANKL-transfected NRK cells[1]. Anti-Mouse RANKL/CD254 Antibody (IK22/5) (0-1000 nM, 3-5 days) drastically inhibited the formation of TRAP+ multinucleated cells in a dose-dependentmanner[1].
References:
[1]. Kamijo S, et al. Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochem Biophys Res Commun. 2006 Aug 18;347(1):124-32.
[2]. Ahern E, et al. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. Clin Cancer Res. 2017 Oct 1;23(19):5789-5801.
[3]. Xiong J, et al. RANKL Mediates Muscle Atrophy and Dysfunction in a Cigarette Smoke-induced Model of Chronic Obstructive Pulmonary Disease. Am J Respir Cell Mol Biol. 2021 May;64(5):617-628.
In Vivo, Anti-Mouse RANKL/CD254 Antibody (IK22/5) (300 μg/mouse, i.p., three times per week, for 14-21 days) significantly reduces bone erosion and osteoporosis in male DBA/1 mice with collagen induced arthritis (CIA)[1]. Anti-Mouse RANKL/CD254 Antibody (IK22/5) (200 μg, i.p., on day -1, 0, and 2) significantly reduces the number of lung metastatic nodules combined with anti-CTLA4 mAb in C57BL/6 wild-type (WT) mice bearing B16F10 or RM-1 lung metastasis[2]. Anti-Mouse RANKL/CD254 Antibody (IK22/5) (200 μg, i.p., once every 2-4 days, from day 3 to 12) significantly inhibits tumor growth combined with anti-CTLA4 mAb in C57BL/6 WT mice bearing B16F10 tumors or CT26 tumors[2]. Anti-Mouse RANKL/CD254 Antibody (IK22/5) (100 or 250 μg, i.p., twice weekly, for 24 weeks) significantly improves muscle atrophy and its function in female C57BL/6 mice with a cigarette smoke (CS) exposure induced chronic obstructive pulmonary disease (COPD) model[3].
In Vitro, Anti-Mouse RANKL/CD254 Antibody (IK22/5) (3-5 days) dose dependently inhibits osteoclast differentiation by blocking the RANKL/RANK interaction in mouse RANKL-transfected NRK cells[1]. Anti-Mouse RANKL/CD254 Antibody (IK22/5) (0-1000 nM, 3-5 days) drastically inhibited the formation of TRAP+ multinucleated cells in a dose-dependentmanner[1].
References:
[1]. Kamijo S, et al. Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochem Biophys Res Commun. 2006 Aug 18;347(1):124-32.
[2]. Ahern E, et al. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. Clin Cancer Res. 2017 Oct 1;23(19):5789-5801.
[3]. Xiong J, et al. RANKL Mediates Muscle Atrophy and Dysfunction in a Cigarette Smoke-induced Model of Chronic Obstructive Pulmonary Disease. Am J Respir Cell Mol Biol. 2021 May;64(5):617-628.